Deconstructing feedback-signaling networks to improve anticancer therapy with mTORC1 inhibitors.
about
Drosophila Lung Cancer Models Identify Trametinib plus Statin as Candidate TherapeuticNelfinavir and other protease inhibitors in cancer: mechanisms involved in anticancer activityTAK-228 (formerly MLN0128), an investigational oral dual TORC1/2 inhibitor: A phase I dose escalation study in patients with relapsed or refractory multiple myeloma, non-Hodgkin lymphoma, or Waldenström's macroglobulinemia.Preclinical pharmacological evaluation of a novel multiple kinase inhibitor, ON123300, in brain tumor modelsIn-vitro and in-vivo combined effect of ARQ 092, an AKT inhibitor, with ARQ 087, a FGFR inhibitor.Review: molecular pathology in adult high-grade gliomas: from molecular diagnostics to target therapiesActivation of PI3K/AKT and MAPK pathway through a PDGFRβ-dependent feedback loop is involved in rapamycin resistance in hepatocellular carcinoma.Regulation of insulin-like growth factor signaling by metformin in endometrial cancer cellsEffects of mTOR inhibitor everolimus (RAD001) on bladder cancer cells.Control of mTORC1 signaling by the Opitz syndrome protein MID1.Calcium signals inhibition sensitizes ovarian carcinoma cells to anti-Bcl-xL strategies through Mcl-1 down-regulation.The challenges and the promise of molecular targeted therapy in malignant gliomas.Interaction of mTOR and Erk1/2 signaling to regulate oligodendrocyte differentiation.Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR inhibitors: rationale and importance to inhibiting these pathways in human health.Novel roles for LIX1L in promoting cancer cell proliferation through ROS1-mediated LIX1L phosphorylation.Combination of Rad001 (everolimus) and propachlor synergistically induces apoptosis through enhanced autophagy in prostate cancer cellsTargeting the Mammalian Target of Rapamycin (mTOR) in Cancer Therapy: Lessons from Past and Future PerspectivesDominant roles of the Raf/MEK/ERK pathway in cell cycle progression, prevention of apoptosis and sensitivity to chemotherapeutic drugs.The Raf/MEK/ERK pathway can govern drug resistance, apoptosis and sensitivity to targeted therapy.Enhancing therapeutic efficacy by targeting non-oncogene addicted cells with combinations of signal transduction inhibitors and chemotherapyThe AMPK agonist AICAR inhibits the growth of EGFRvIII-expressing glioblastomas by inhibiting lipogenesis.Molecular mechanisms of tumor resistance to PI3K-mTOR-targeted therapy.Targeting mTOR with rapamycin: one dose does not fit allTargeted therapy for malignant glioma patients: lessons learned and the road ahead.Impact of dual mTORC1/2 mTOR kinase inhibitor AZD8055 on acquired endocrine resistance in breast cancer in vitro.Oxidative stress downstream of mTORC1 but not AKT causes a proliferative defect in cancer cells resistant to PI3K inhibitionBrain tumor stem cells as therapeutic targets in models of glioma.Therapeutic resistance resulting from mutations in Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR signaling pathways.Naturally occurring, tumor-specific, therapeutic proteins.Current clinical development of PI3K pathway inhibitors in glioblastoma.Molecular targeted therapy in recurrent glioblastoma: current challenges and future directions.Everolimus in colorectal cancer.Combination of Arsenic trioxide and Everolimus (Rad001) synergistically induces both autophagy and apoptosis in prostate cancer cellsStrategies to avoid treatment-induced lineage crisis in advanced prostate cancer.Regulation of onco and tumor suppressor MiRNAs by mTORC1 inhibitor PRP-1 in human chondrosarcoma.Role of aberrant PI3K pathway activation in gallbladder tumorigenesis.MEK inhibition leads to PI3K/AKT activation by relieving a negative feedback on ERBB receptors.mTORC1 inhibition and ECM-cell adhesion-independent drug resistance via PI3K-AKT and PI3K-RAS-MAPK feedback loops.Limitations in small intestinal neuroendocrine tumor therapy by mTor kinase inhibition reflect growth factor-mediated PI3K feedback loop activation via ERK1/2 and AKT.AKT can modulate the in vitro response of HNSCC cells to irreversible EGFR inhibitors.
P2860
Q27319935-EA89AC4D-E270-4DF9-85B4-299F0FC5EEC7Q28083142-5FCC2000-E71C-46FE-9F01-F25455A8C4F2Q33429430-AD0253B7-9894-49E3-9621-7B6C4529B093Q33578960-628997D4-65F2-49D2-9DF7-F23428A9621FQ33601377-C2C9C807-6446-47A8-8409-77158A5C1D49Q33925544-28D16138-B102-4081-BB4A-6FB18957511DQ34200875-2A3771F4-6C53-4F58-BA6F-319776C90880Q34293099-5C4A4061-52E9-40B9-ADA5-EB91C7AE3CFFQ34743802-BD2A59D2-9DDB-424D-8F99-E3AA670BF8ADQ35008479-D6145170-9465-48FE-8F29-2B564BF224ADQ35143875-A8473DDF-38FE-4C26-B65A-34796D6240F3Q35214534-4F908F1A-7BA5-4910-A0FA-C9F2BA46EF86Q35523618-F0E4222A-D7C6-4AE2-B80F-8CDDED912888Q35679353-B667973D-1B3F-4123-98D8-51FECD7CC7DDQ35999416-E937380F-5D18-4389-82FC-01DF23BAE000Q36028196-23AD266D-5A61-4257-8972-7AA95CF34A35Q37132788-A1843BD2-0C82-4D71-8D3D-F6D369F57DC1Q37192602-25BB6B76-FBA0-4456-AE06-FC017B22E700Q37192611-8C8B5EE3-95EA-4077-A16A-CE1B10608AA5Q37192616-70665E90-5B00-4A75-A135-6A89A5DBAFF5Q37271256-C016D1B6-6525-4B13-992E-97FCC05A385FQ37354089-E5A6E2BE-5568-4F7C-950E-86C8716B4E72Q37409171-29379388-7AF0-4EF9-8BA7-6D87B2855553Q37533648-C9C93A4C-9662-493C-BD51-4BF7EEDBECE4Q37690245-83524457-4B88-448A-ACB9-E596E46F5673Q37716027-A96FED84-2E77-4791-BB1E-39B30CC2F51CQ37773191-322C4616-D4DB-456E-BFCF-3CD52342E8DEQ37837732-FE92D3E3-1F0E-4E0E-BAE7-34409B737AA3Q37869260-170B8FC7-B2B4-453E-9CDC-D108307E8FE8Q38012438-39A3E037-6ABE-4B42-B4EB-417821CE4746Q38021521-9723E5A3-6E69-4DEC-8D7B-044DB5EE2B43Q38081233-A95B5088-ED4D-4256-B9EF-A7743068E829Q38722639-A75B4D94-F6FE-4458-8833-0A0F95AE80EAQ39016544-7743856F-D47A-4077-A80C-2BBD8FC9DC65Q39068017-58D6E98F-59C7-41FE-8A64-7AF4C4E318F4Q39285469-1C708178-50B5-4418-B72A-FF80072AE2BEQ39355055-0D4E3F05-92F4-47E0-B071-2209528AB9AAQ39411901-C1DBC87D-7430-4C57-BE82-900B97CED43FQ39579138-027E4BC7-E58B-41CA-868E-D10EDAA1A1A2Q41593135-E37DEF4F-75B8-43CF-A0F6-E1D44286261D
P2860
Deconstructing feedback-signaling networks to improve anticancer therapy with mTORC1 inhibitors.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 22 December 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Deconstructing feedback-signal ...... herapy with mTORC1 inhibitors.
@en
Deconstructing feedback-signal ...... herapy with mTORC1 inhibitors.
@nl
type
label
Deconstructing feedback-signal ...... herapy with mTORC1 inhibitors.
@en
Deconstructing feedback-signal ...... herapy with mTORC1 inhibitors.
@nl
prefLabel
Deconstructing feedback-signal ...... herapy with mTORC1 inhibitors.
@en
Deconstructing feedback-signal ...... herapy with mTORC1 inhibitors.
@nl
P2860
P356
P1433
P1476
Deconstructing feedback-signal ...... herapy with mTORC1 inhibitors.
@en
P2093
Arkaitz Carracedo
P2860
P304
P356
10.4161/CC.7.24.7244
P577
2008-12-22T00:00:00Z